Johns Hopkins researchers found its early uptake curve was 4.4 times steeper than Zepbound's, and injectable Wegovy prescriptions didn't fall after the pill arrived.
Recap by typeshit. Full story at MPR.
A comment-for-link Instagram post saying trials of semaglutide, tirzepatide and retatrutide showed up to 28% weight loss. Little detail beyond that.
Real-world records shown at EASD 2026 had 24.1% of tirzepatide users losing 15% or more in a year, versus about 9% on semaglutide, GlobalData reports.
Survey data on 3,615 US adults showed about 30% lower odds of GLP-1 use among cancer survivors, despite more heart and kidney disease. Causes remain unclear.
11:38
RMZ digs into why weight loss results on tirzepatide vary so widely, with some people losing double what others do.
Per Reuters, the company says both generic Ozempic versions remain available for diabetes treatment and weight management.
SIA LearnBetter rates each claimed use from Proven to Failed and lists legal status in ten regions, in six languages. It says entries haven't yet been reviewed by a clinician.
Loading…